Anebulo Pharmaceuticals, Inc. (ANEB)
NASDAQ: ANEB · IEX Real-Time Price · USD
3.080
+0.180 (6.21%)
Mar 28, 2024, 3:58 PM EDT - Market closed
Company Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction.
The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.
Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc.
Country | United States |
Founded | 2020 |
IPO Date | May 7, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 2 |
CEO | Richard Anthony Cunningham |
Contact Details
Address: Jfl Capital Management, 1017 Rr 620 S, Suite 107 Lakeway, Texas 78734 United States | |
Phone | 737 203 5270 |
Website | anebulo.com |
Stock Details
Ticker Symbol | ANEB |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
IPO Price | $7.00 |
CIK Code | 0001815974 |
CUSIP Number | 034569103 |
ISIN Number | US0345691036 |
Employer ID | 85-1170950 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Joseph F. Lawler M.D., Ph.D. | Founder and Chairman |
Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer |
Richard Anthony Cunningham | Chief Executive Officer and Director |
Daniel V. George | Principal Accounting Officer, Acting Chief Financial Officer and Secretary |
Scott L. Anderson | Head of Investor Relations and Public Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 13, 2024 | 10-Q | Quarterly Report |
Feb 13, 2024 | 8-K | Current Report |
Nov 21, 2023 | 8-K | Current Report |
Nov 14, 2023 | 10-Q | Quarterly Report |
Nov 14, 2023 | 8-K | Current Report |
Oct 30, 2023 | ARS | Filing |
Oct 30, 2023 | DEF 14A | Other definitive proxy statements |
Oct 19, 2023 | PRE 14A | Other preliminary proxy statements |
Oct 6, 2023 | 8-K | Current Report |
Sep 29, 2023 | 8-K | Current Report |